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The prevalence of type 2 diabetes among Australian residents is 7.5%; however, prevalence rates up to six times
higher have been reported for indigenous Australian communities. Epidemiological evidence implicates genetic
factors in the susceptibility of indigenous Australians to type 2 diabetes and supports the hypothesis of the “thrifty
genotype,” but, to date, the nature of the genetic predisposition is unknown. We have ascertained clinical details
from a community of indigenous Australian descent in North Stradbroke Island, Queensland. In this population,
the phenotype is characterized by severe insulin resistance. We have conducted a genomewide scan, at an average
resolution of 10 cM, for type 2 diabetes–susceptibility genes in a large multigeneration pedigree from this community.
Parametric linkage analysis undertaken using FASTLINK version 4.1p yielded a maximum two-point LOD score
of +2.97 at marker D2S2345. Multipoint analysis yielded a peak LOD score of +3.9 !1 cM from marker D2S2345,
with an 18-cM 3-LOD support interval. Secondary peak LOD scores were noted on chromosome 3 (+1.8 at
recombination fraction [v] 0.05, at marker D3S1311) and chromosome 8 (+1.77 at , at marker D8S549).vp 0.0
These chromosomal regions are likely to harbor novel susceptibility genes for type 2 diabetes in the indigenous
Australian population.
Introduction
Type 2 diabetes (MIM 125853) is characterized by hy-
perglycemia due to impaired insulin secretion, insulin
resistance in muscle, and nonsuppressible hepatic glu-
cose production (DeFronzo 1988). Genetic factors play
an important role in the development of diabetes. The
monogenic forms of diabetes account for ∼5% of cases
and are caused by mutations in genes encoding insulin,
the insulin receptor, glucokinase, and the transcription
factors hepatocyte nuclear factor-1a, (HNF-1a), HNF-
1b, HNF-4a, insulin promoter factor-1, and NeuroD1/
BETA2 (Steiner et al. 1995; Taylor 1995; Bell et al. 1996;
Yamagata et al. 1996a, 1996b; Horikawa et al. 1997;
Stoffers et al. 1998; Malecki et al. 1999). Mutations in
mitochondrial genes can cause diabetes, often in asso-
ciation with hearing loss (Maassen and Kadowaki
1996). There has been relatively little progress in iden-
tifying the genes responsible for the more common late-
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onset forms of type 2 diabetes. These late-onset forms
do not have a simple Mendelian genetic basis and are
thought to result from the joint action of and complex
interaction between genetic and environmental factors.
Type 2 diabetes is a major public health problem. The
overall prevalence of type 2 diabetes among Australians
aged 125 years is 7.5% (Zimmet and Welborn 2001).
Prevalence rates up to six times higher have been re-
ported in indigenous Australian communities (Bastian
1979), with a lower average age at onset of type 2
diabetes. The epidemiological and pathophysiological
characteristics of type 2 diabetes support the hypothesis
of the “thrifty genotype” (Neel 1963), but, to date, the
nature of the genetic predisposition is largely unknown.
The high prevalence of type 2 diabetes and associated
metabolic disturbances in indigenous Australians are
major factors contributing to high morbidity and mor-
tality in this group (O’Dea 1992). In the group 35–54
years of age, the prevalence of diabetes in indigenous
Australians is 20%–25%. Complications including re-
nal failure, blindness, and foot ulcers leading to am-
putation are common. The clustering of hyperglycemia
with insulin resistance, elevated plasma triglyceride, low
HDL cholesterol, hypertension, and central obesity pre-
disposes to macrovascular disease (O’Dea et al. 1990;
O’Dea 1991; Guest et al. 1993; Gault et al. 1996; Hay-
man 1997).
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Epidemiological evidence strongly implicates genetic
factors in the susceptibility of indigenous Australians to
type 2 diabetes. One line of evidence for genetic influ-
ences underlying ethnic differences in diabetes preva-
lence is the fact that diabetes and insulin resistance are
inversely related to the amount of European admixture
present in a population. Among indigenous Australians
in New South Wales, the prevalence of diabetes was
twice as high in inland towns as in coastal towns where
European admixture was common (Williams et al.
1987). In a survey in central Australia, glucose intol-
erance and 2-h insulin levels were inversely related to
European admixture (O’Dea et al. 1993). Such genetic
effects, however, must depend on interaction with en-
vironmental factors, such as weight gain and low phys-
ical activity, since type 2 diabetes has remained uncom-
mon among indigenous Australians who are able to
continue living as hunter-gatherers (O’Dea 1992).
There are complexities involved in the mapping of
diabetes-susceptibility genes. Different ethnic groups
have distinct population histories and, in each popu-
lation, different genes are likely to be responsible for
disease susceptibility. Research efforts to date have
largely centered on ethnic groups in the United States,
Finland, and Western Europe. The genetic analysis of
the indigenous Australian population is likely to make
a unique contribution to the understanding of diabetes
susceptibility and resistance. The major aim of this re-
search program is the identification of susceptibility
genes for type 2 diabetes in Australian indigenous ped-
igrees. The clinical relevance of this includes (i) the de-
velopment of preclinical screening for at-risk individuals
and (ii) the discovery of novel drug targets that may
prove amenable to new forms of therapy for type 2
diabetes, both in these populations and more generally.
Methods
We have ascertained clinical details from a community
of indigenous Australian descent in North Stradbroke
Island, Queensland. We have conducted a genomewide
scan, at an average resolution of 10 cM, for type 2 di-
abetes–susceptibility genes and have undertaken linkage
and quantitative-trait analysis in a large multigeneration
pedigree from this community (fig. 1). The pedigree con-
sists of 232 living members, 56 of whom are affected
with type 2 diabetes. To date, 138 individuals from the
pedigree who are 118 years of age, including 49 who
have diabetes, are participating in the study, with re-
cruitment ongoing. The study protocol was approved by
the Princess Alexandra Hospital Ethics Committee, and
all participants provided informed consent before the
study. These studies have been performed after full con-
sultation with and with the approval of the community.
Clinical Studies
The protocol included an interview that recorded age
at onset of diabetes, history of treatment and complica-
tions, and measurements of height, weight, body-mass
index (BMI), blood pressure, and waist and hip circum-
ference. A fasting blood sample was taken for measure-
ments of glucose, lipids, and C-peptide. The fasting
plasma glucose and C-peptide concentrations were inte-
grated by homeostasis-model assessment (HOMA) of
beta-cell function and insulin sensitivity (Matthews et al.
1985; Levy et al. 1991). Beta-cell function and insulin
sensitivity measured by HOMA have been shown to cor-
relate with measures obtained by hyperglycemic and eu-
glycemic clamp studies (Matthews et al. 1985; Levy et al.
1991). Individuals were considered “affected” for the
linkage analysis if they met one of the following criteria
(Expert Committee on the Diagnosis and Classification
of Diabetes Mellitus 1997): (i) previously diagnosed type
2 diabetes being treated with medical therapy or (ii) fast-
ing plasma glucose 7 mmol/liter. Normoglycemia was
defined as fasting plasma glucose !6.1 mmol/liter. Subjects
with fasting plasma glucose 6.1 mmol/liter and !7.0
mmol/liter were classified as having impaired fasting glu-
cose. The subjects considered affected with type 2 diabetes
had no history of ketosis, had been treated for 3 mo
by diet or by oral hypoglycemic agents, and had meas-
urable C-peptide levels. The mean age of the subjects with
diabetes was 5412 years (1 SD), the mean BMI was
327 kg/m2, the median HOMA insulin sensitivity was
16% (interquartile range 11%–29%), and the median
HOMA beta-cell function was 166% (interquartile range
89%–237%).
Molecular Studies
DNA was prepared from peripheral lymphocytes. The
subjects were genotyped with 474 autosomal markers,
with an anticipated average heterozygosity of 0.74
0.11 (meanSD), at the Australian Genome Research
Facility. The mean sex-averaged distance between ad-
jacent markers is 8.66.5 cM (range 0–34 cM). The
pedigree structure was validated by genotypic profiling/
haplotyping. Marker-error checking, marker-map eval-
uation, and allele-frequency estimation were undertaken
as described elsewhere (Ewen et al. 2000). The ge-
nomewide scan was performed on 97 subjects, of whom
45 had type 2 diabetes. Fine mapping was performed
on a total of 136 subjects, of whom 49 had type 2
diabetes.
Linkage Analysis
Two-point and multipoint parametric analyses were
performed using FASTLINK version 4.1p (Cottingham
et al. 1993; Schaffer et al. 1994) with an autosomal
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Figure 1 Pedigree structure. Blackened symbols denote individuals with type II diabetes. Unblackened symbols denote unaffected indi-
viduals. The arrow indicates the proband.
dominant, three-liability-class model and age-dependent
penetrance factors. For ease of computation, the large
pedigree was split into two. Simple counting estimates
were used to calculate allelic frequencies within the ped-
igree. The genetic model used for the linkage analysis
was an ad hoc model chosen to approximate the high
cumulative incidence and recurrence risks of diabetes in
this sample and was selected prior to these linkage anal-
yses. We have not used a MOD (i.e., maximized-over-
trait-model) approach. A dominant model was chosen,
because of the density and pattern of disease in the ped-
igree. The penetrances in the three age classes were cho-
sen to match the empiric Kaplan-Meier age-at-onset
curves for the pedigree, bearing in mind that diagnosis
in the earlier generations was delayed or absent. The
three liability classes defined on the basis of age were as
follows: class 1, age 165 years; class 2, age 45–65 years;
and class 3, age !45 years. Phenocopy rates used in each
liability class to accommodate potential heterogeneity
were 0.2, 0.05, and 0.0001, respectively, and hetero-
zygous and homozygous dominant penetrance factors
were 0.99, 0.7, and 0.1, respectively. The disease-allele
frequency is necessarily high, because of the high lifetime
risk. Disease-gene frequency was set to define a 30%
population prevalence, with a maximum sporadic (non-
inherited) frequency of 40%. This model leads to high
baseline population rates of 20–30% and a sibling re-
currence ratio of 1.8–2.5 and is consistent with preva-
lence data from the community (Shaw et al. 2000). The
original analysis was performed with only overt diabetes
classed as “affected.” A secondary analysis was carried
out including impaired fasting glucose subjects in the
“affected” classification.
Results
Peak two-point LOD scores from the genomewide scan
are presented in figure 2. Suggestive linkage was indi-
Figure 2 Graphs of two-point LOD scores at , for each autosome from the genomewide scan. The x-axes represent distance invp 0.01
centimorgans, and the y-axes represent two-point LOD scores.
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Table 1
Peak Two-Point LOD Scores for Chromosome
2q Markers
Marker LOD Score v
Locationa
(Mb)
D2S2313 .11 .1 156.4
D2S142 .57 .1 166.3
D2S2157 .51 .05 175.1
D2S2330 2.61 .01 175.5
D2S2345 2.97 .01 177.2
D2S335 1.27 .05 182.5
D2S364 .12 .1 192.9
a Location is according to Genethon Data-
base and is taken from the Genome Browser Oct
2000 freeze.
cated on chromosome 2, with a peak two-point LOD
score of 2.61 at marker D2S2330 (recombination frac-
tion [v] 0.01). Fine mapping in the expanded data set
was performed in this region, with a maximum two-
point LOD score of2.97 at D2S2345 ( ) (tablevp 0.01
1). Multipoint analysis yielded a peak multipoint LOD
score of 3.9, !1 cM from marker D2S2345, with a 3-
LOD support interval of 18 cM (fig. 3). Secondary peak
two-point LOD scores on the genomewide scan were
noted on chromosome 8p (LOD score 1.77 and vp
at D8S549) and chromosome 3q (LOD score 1.80
and at D3S1311). Two-point analysis of thevp 0.05
genomewide scan data, when individuals with impaired
fasting glucose were considered to be “affected,” did not
remove these peaks, with peak two-point LOD scores
of 1.79 at D2S2330 ( ), 1.51 at D3S1311vp 0.05
( ) and 1.81 at D8S549 ( ). Analysis ofvp 0.05 vp 0
the fine-mapping data in the chromosome 2 region gave
a peak two-point LOD score of 1.96 at D2S2345
( ) and a peak multipoint LOD score of 2.72vp 0.05
at marker D2S2345.
Discussion
The genetic analysis of type 2 diabetes is challenging
because of the disease’s etiological complexity and ge-
netic heterogeneity. Positive linkages with type 2 diabetes
have been identified in a number of populations. Hanis
et al. (1996) reported linkage with type 2 diabetes in
Mexican-American affected sib pairs, at marker
D2S125, in a region termed NIDDM1 (MIM 601283).
The evidence for linkage was associated with a common
GrA polymorphism (UCSNP-43) within the calpain-10
gene (CAPN10 [MIM 605286]) (Horikawa et al. 2000).
Pima Indians with normal glucose tolerance who have
a G/G genotype at UCSNP-43 were found to have de-
creased rates of postabsorptive and insulin-stimulated
glucose turnover, resulting from decreased rates of glu-
cose oxidation, and G/G homozygotes were found to
have reduced CAPN10 mRNA expression in skeletal
muscle (Baier et al. 2000). Mahtani et al. (1996) de-
scribed linkage of MODY3-linked markers with type 2
diabetes in a subset of families from an isolated popu-
lation in western Finland, in the absence of mutations
in HNF-1a. Those authors inferred the presence of a
gene in this region (NIDDM2 [MIM 601467]) that af-
fects susceptibility to adult-onset diabetes associated
with low insulin secretion. Shaw et al. (1998) identified
positive linkage with the NIDDM2 region in a large
pedigree of admixed European/Pacific Islander descent.
Elbein et al. (1999) conducted a genomewide scan in
Utah families of northern European ancestry, and a locus
on chromosome 1q21-23 met genomewide criteria for
significant linkage. Sib-pair analyses in the Pima Indian
population indicated a diabetes-susceptibility locus on
chromosome 1 (LOD score 4.1 at D1S127) (Hanson
et al. 1998). A number of studies of different populations
have found evidence for linkage on 20q in the MODY1
region, in the absence of mutations in HNF-4a (Bowden
et al. 1997; Ji et al. 1997; Zouali et al. 1997; Malecki
et al. 1998; Ghosh et al. 1999). These data indicate that
type 2 diabetes is a heterogeneous disorder, with differ-
ent genetic regions implicated in different populations.
There has been replication of positive results in the
regions of the MODY1 and MODY3 genes and on chro-
mosome 1q, adding weight to the hypothesis that novel
diabetes-susceptibility genes relevant to a number of
populations are located in these regions.
Our data represent the first full-genome linkage anal-
ysis performed in an indigenous Australian pedigree.
Type 2 diabetes in the indigenous Australian population
is characterized by severe and predominant insulin re-
sistance (Guest et al. 1993). Indigenous Australians have
a sixfold increased risk of diabetes compared with Aus-
tralians of European descent, and this risk is modulated
by European admixture (Williams et al. 1987; O’Dea
et al. 1993). Our hypothesis is that the indigenous Aus-
tralian population harbors unique susceptibility genes
for type 2 diabetes; however, the pathways involved may
also have relevance to other ethnic groups, in terms of
etiology and therapeutic potential. The advantages of
studying this population include the availability of large
pedigrees arising from a limited number of founders,
giving statistical power to the analysis and reducing
potential genetic heterogeneity.
The strongest evidence for multipoint linkage was
found on chromosome 2q24.3 at D2S2345, with a two-
point LOD score of 2.97 and a multipoint LOD score
of 3.9 !1 cM centromeric to D2S2345. D2S2330,
which gave the original peak two-point LOD score in
this region, has previously been implicated by Vionnet
et al. (2000), who found linkage with a maximum-bi-
nomial-likelihood LOD score and maximized LOD
score of 1.25 and 1.22, respectively, at marker
D2S2330. This linkage was in French whites, with af-
fected status including both overt diabetes and glucose
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Figure 3 Graph of multipoint LOD scores for chromosome 2q. Marker positions are sex-averaged and are calculated on the basis of The
Genetic Location Database.
intolerance with a BMI !27 kg/m2. This is in contrast
with the diagnostic criteria used and the clinical features
of affected subjects in the present study, who have BMI
of 327 kg/m2. Duggirala et al. (2001) found suggestive
linkage to fasting-specific insulin in nondiabetic Mexi-
can Americans, with a LOD score of 2.7 at marker
D2S142. D2S142 is ∼10 Mb centromeric to D2S2330.
These data give further support to the location of a type
2 diabetes–susceptibility gene in this region, across a
number of different ethnic groups. The region is located
∼66 Mb centromeric to marker D2S362, for which pos-
itive linkage has been demonstrated in Mexican Amer-
ican subjects (Ehm et al. 2000), and ∼87 Mb centrom-
eric to the NIDDM1 locus (Hanis et al. 1996).
Candidate genes within the region of interest on 2q
include the gene encoding growth-receptor–binding
protein 14 (Grb14 [MIM 601524]). Grb14 belongs to
the Grb7 family and binds to receptor tyrosine kinases
and tyrosine-phosphorylated proteins. Grb10 and
Grb14 have been shown to bind the insulin receptor
and are negative regulators of insulin signalling. Ov-
erexpression of Grb14 in Chinese hamster ovary cells
stably expressing the insulin receptor results in de-
creased insulin stimulation of glycogen synthesis, ac-
companied by decreased tyrosine phosphorylation of
insulin substrate-1. This would result in dysregulation
of the downstream signalling component of insulin-
mediated pathways (Kasus-Jacobi et al. 1998; Hem-
ming et al. 2001). Another candidate in the region is
the gene encoding islet-specific glucose-6-phosphate
catalytic subunit–related protein. The activity of the
glucose-6-phosphatase catalytic subunit is elevated in
islets isolated from ob/ob mice, leading to increased
glucose cycling and reduced glucose-stimulated insulin
secretion (Khan et al. 1995; Ebert et al. 1999). Close
to D2S142 and ∼10 Mb from our peak LOD score are
the genes for mitochondrial glycerol-3-phosphate de-
hydrogenase 2 (MIM 138430), which possibly has a
role to play in glucose-stimulated insulin secretion
(Ferrer et al. 1996), and the inwardly rectifying po-
tassium channel KCNJ3 (MIM 601534), which has
been implicated in the regulatory pathways of insulin
secretion (Vionnet et al. 1997).
To identify additional chromosomal regions that are
likely to harbor genes affecting susceptibility to type 2
diabetes, we adopted more-liberal criteria than those
proposed by Lander and Kruglyak (1995) to identify
regions with positive results. Following the recommen-
dations of Rao and Province (2000) we considered a P
value of !.0023 as “highly suggestive” evidence for link-
age and a P value !.01 as “suggestive” evidence for
linkage. These P values correspond to LOD scores of
1.75 and 1.18, respectively. These more liberal criteria
maximize the detection of genomic regions to be con-
sidered for further investigation while allowing true neg-
ative results to be reported. On chromosomes 3q29 and
8p22 there was highly suggestive evidence for linkage,
with LOD scores of 1.8 at for markervp 0.05
D3S1311 and 1.77 for marker D8S549. Whereas the
region on chromosome 8p22 has not previously been
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linked to type 2–diabetes susceptibility, several studies
have found the region on chromosome 3q27-qter to
have positive linkage to metabolic traits and type 2 di-
abetes (Hegele et al. 1999; Kissebah et al. 2000; Vionnet
et al. 2000). Kissebah et al. (2000) reported linkage of
six quantitative traits representative of the metabolic
syndrome to 3q27, in 507 white nuclear families. These
traits gave peak LOD scores of 2.37–3.54 between
markers D3S2427 and D3S2418. An indication of link-
age between type 2 diabetes and D3S2418 was also
reported by Hegele et al. (1999), in a genomewide scan
in Canadian Oji-Cree. Vionnet et al. (2000) also re-
ported linkage to 3q27-qter in French nuclear families
and sib pairs with a relatively early age at onset (age
!46 years). These reports are all within 20 cM of our
peak LOD score at D3S1311 and support the presence
of a diabetes-susceptibility gene in this region. Fine map-
ping will be undertaken in both the 8p and 3q regions.
Several candidate genes of potential interest have been
identified in the region of these secondary peaks, in-
cluding lipoprotein lipase on chromosome 8p, which
has been associated with insulin resistance in Mexican
Americans (Yang et al. 2001), and type 1 protein phos-
phatase inhibitor 2 (MIM 601792), which reversibly
inhibits and facilitates the correct conformational ar-
rangement of the catalytic subunits of type 1 protein
phosphatase, an activator of glycogen synthase (Alessi
et al. 1993).
In conclusion, on the basis of a genomewide scan, we
have identified a region of significant positive linkage
with type 2 diabetes on chromosome 2q. Several can-
didate genes have been identified in the region, and we
plan to continue fine mapping, haplotype analysis, and
sequence analysis, to identify the nature of the causative
gene. The identification of genetic markers for type 2
diabetes is fundamental for understanding the cause of
the disease, for identifying subjects at risk at a preclin-
ical stage, and for the development of more-effective
preventative and therapeutic strategies for the manage-
ment of the condition.
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